Literature DB >> 15585909

Exploiting dendritic cells for active immunotherapy of cancer and chronic infection.

David O'Neill1, Nina Bhardwaj.   

Abstract

Dendritic cells (DC) are important antigen-presenting cells (APC) that can prime naive T-cells and control lymphocyte-mediated adaptive immune responses with respect to magnitude, memory, and self-tolerance. Understanding the biology of these cells is central to the development of new generation immunotherapies for cancer and chronic infection. This chapter presents a brief overview of DC biology and the preparation and use of DC-based vaccines.

Entities:  

Mesh：

Year:  2005        PMID： 15585909

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN： 1543-1894


  6 in total

1.  Generation of feline dendritic cells derived from peripheral blood monocytes for in vivo use.

Authors:  Giulia Freer; Donatella Matteucci; Paola Mazzetti; Leonia Bozzacco; Mauro Bendinelli
Journal:  Clin Diagn Lab Immunol       Date:  2005-10

2.  A new TLR2 agonist promotes cross-presentation by mouse and human antigen presenting cells.

Authors:  Melissa Santone; Susanna Aprea; Tom Y H Wu; Michael P Cooke; M Lamine Mbow; Nicholas M Valiante; James S Rush; Stephanie Dougan; Ana Avalos; Hidde Ploegh; Ennio De Gregorio; Cecilia Buonsanti; Ugo D'Oro
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity.

Authors:  Mojca Skoberne; Alice Yewdall; Keith S Bahjat; Emmanuelle Godefroy; Peter Lauer; Edward Lemmens; Weiqun Liu; Will Luckett; Meredith Leong; Thomas W Dubensky; Dirk G Brockstedt; Nina Bhardwaj
Journal:  J Clin Invest       Date:  2008-11-06       Impact factor: 14.808

4.  A novel DC therapy with manipulation of MKK6 gene on nickel allergy in mice.

Authors:  Megumi Watanabe; Naozumi Ishimaru; Meinar Nur Ashrin; Rieko Arakaki; Akiko Yamada; Tetsuo Ichikawa; Yoshio Hayashi
Journal:  PLoS One       Date:  2011-04-22       Impact factor: 3.240

5.  Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus.

Authors:  Marcin Kwissa; Rama R Amara; Harriet L Robinson; Bernard Moss; Sefik Alkan; Abdul Jabbar; Francois Villinger; Bali Pulendran
Journal:  J Exp Med       Date:  2007-10-22       Impact factor: 14.307

6.  Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients.

Authors:  Daiqing Gao; Changyou Li; Xihe Xie; Peng Zhao; Xiaofang Wei; Weihong Sun; Hsin-Chen Liu; Aris T Alexandrou; Jennifer Jones; Ronghua Zhao; Jian Jian Li
Journal:  PLoS One       Date:  2014-04-03       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.